Clinical trials: Hepatitis A, open to volunteers
Immune-Mediated Hepatitis
Checkpoint Inhibitor-induced Liver Injury
In this multi-center prospective observational study, the investigators plan to identify the incidence and risk factors for checkpoint inhibitor-induced liver injury and characterize biochemical, genetic, immunological, and…
- Trial name
- ChILI (NCT04476563)
- Testing
- Obtaining biological samples
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- University of Nottingham
Liver Cirrhosis
Faecal Microbiota Transplantation for Liver Cirrhosis
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis.
- Trial name
- CHiFT (NCT04932577)
- Testing
- Faecal microbiota transplantation
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- University of Aarhus
Hepatitis B, Hepatocellular Carcinoma (HCC)
TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma
Study Objective: To compare the efficacy and prognosis of systemic cancer therapy between TAF monotherapy and ETV plus TAF combination therapy in patients with unresectable, advanced hepatitis-B-related hepatocellular carcinoma…
- Trial name
- NCT07253220
- Testing
- The arm will receive combination therapy (entecavir 0.5 mg once daily plus TAF 25 mg once daily); after HBV DNA becomes undetectable, the combination group will switch to TAF monotherapy., TAF monotherapy
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC)
Role of Long Noncoding RNA LINC01134 in Metastasis of Hepatitis C Virus-related Hepatocellular Carcinoma
LINC01134, a novel lncRNA, has received increasing attention in cancer research, particularly in hepatocellular carcinoma (HCC).
- Trial name
- NCT07130474
- Volunteers
- 50 people
- Sponsor
- Sohag University
Immune-mediated Hepatitis
Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors
Identify specific blood biomarkers for hepatitis induced by immune checkpoint inhibitors in comparison to idiopathic autoimmune hepatitis.
- Trial name
- Pro-CHILI (NCT06470997)
- Testing
- Blood sample collection, Liver biopsy
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Montpellier
Hepatitis
Severe Hepatitis Intervention With Emapalumab for Liver Disease
The goal of this study is to see whether a medicine called emapalumab, a monoclonal antibody, is safe and works well for patients aged 1 year and older who have indeterminate severe hepatitis with T-cell activation and have not…
- Trial name
- SHIELD (NCT07744919)
- Testing
- Emapalumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Healthcare of Atlanta
Carcinoma, Hepatocellular, Hepatitis C, Chronic
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
- Trial name
- dSEARCH (NCT05870969)
- Testing
- Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Ruijin Hospital
Autoimmune Hepatitis
Belimumab in Autoimmune Hepatitis
Background: Autoimmune hepatitis (AIH) is a rare chronic and lifelong liver disease. Untreated, disease progresses to end-stage cirrhosis and the focus of therapy is with immunosuppression.
- Trial name
- BELief (NCT06381453)
- Testing
- Belimumab Auto-Injector [Benlysta]
- Where
- 6 sites in Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Chronic HBV Infection
Methylene Blue Treatment of Chronic Hepatitis B Virus Infection
HBV infection is a global public health problem. It is estimated that there are more than 250 million HBV carriers worldwide, of whom approximately 600,000 die each year from HBV-related liver disease.
- Trial name
- MB_HBV (NCT06887036)
- Testing
- Methylene Blue
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- Fondazione Epatocentro Ticino
Hepatitis C Virus Infection
Screening, Treatment, and Eradication of Hep C
The aim of this study is to assess the HCV screening rate in Arizona by identification of potential HCV patients/subjects through different methods of communication - text message, email, social media, radio, newspaper ads, and…
- Trial name
- NCT05071261
- Testing
- Hepatitis C Virus Screening
- Volunteers
- 112,136 people, healthy volunteers welcome
- Sponsor
- Liver Institute PLLC
HBV, HCC
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
This study is a prospective, multicenter, real-world cohort study designed to compare the long-term outcomes of chronic hepatitis B patients with a family history of HBV-related hepatocellular carcinoma (HCC) who receive PEG…
- Trial name
- NCT07007286
- Testing
- ETV,TDF,TAF,TMF combination with PEG IFNα-2b, ETV,TDF,TAF or TMF
- Where
- 555 sites in China
- Volunteers
- 1,500 people
- Sponsor
- Peking University First Hospital
HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV)
Combating Related Epidemics in HCV
This is a two-arm cluster randomized control trial to evaluate the effectiveness of a single-visit point-of-care (POC) test and treat bundle (intervention arm) compared to the current standard-of-care (SOC, control arm).
- Conditions
- HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV), HEPATITIS C (HCV)
- Trial name
- CREST (NCT07560046)
- Testing
- Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2
- Volunteers
- 1,280 people
- Sponsor
- Duke University
Leishmaniasis, Leptospirosis
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments).
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever
- Trial name
- SEZAM (NCT06859619)
- Testing
- Peripheral venous blood sample
- Where
- France
- Volunteers
- 183 people
- Sponsor
- University Hospital, Montpellier
Chronic Hepatitis B
SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus
This is a five-year, double blinded, randomised trial of dapagliflozin versus placebo in patients with chronic hepatitis B and DM or IFG complicated with compensated advanced chronic liver disease (cACLD).
- Trial name
- NCT06364930
- Testing
- Dapagliflozin 10mg Tab
- Where
- Hong Kong
- Volunteers
- 412 people
- Sponsor
- Chinese University of Hong Kong
Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B
A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.
This study is conducted as a randomized, double-blind, placebo-controlled, multicenter clinical trial on a background of entecavir therapy.
- Trial name
- NCT07412236
- Testing
- Hydronidone (270mg)
- Where
- China
- Volunteers
- 1,208 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease
- Trial name
- NCT07632677
- Testing
- iLivTouch (Vibration-controlled transient elastography)
- Where
- 22 sites in China
- Volunteers
- 10,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Chronic Hepatitis b
Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study）
Previous clinical practice and exploratory studies suggest that some patients who have not achieved functional cure in the first round of interferon therapy can achieve HBsAg clearance by interferon retreatment (intermittent…
- Trial name
- NCT06323681
- Testing
- Peginterferon α-2b based treatment group, NAs monotherapy group
- Where
- China
- Volunteers
- 2,016 people
- Sponsor
- Qing XIe
Chronic Hepatitis B
Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)
To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.
- Trial name
- NCT03792919
- Testing
- Stop current treatment (anti-HBV neucleos(t)ides), Keep current treatment (anti-HBV neucleos(t)ides)
- Where
- Hong Kong
- Volunteers
- 2,000 people
- Sponsor
- Humanity & Health Medical Group Limited
Liver Fibrosis
Prediction of Significant Liver Fibrosis
The deep learning method based on convolutional neural network (CNN) was used to extract the relevant features of liver fibrosis classification from the multi-modal information of digital pathological sections, clinical…
- Trial name
- PSLF (NCT06509230)
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Huang Haijun
Chronic Hepatitis B Virus (HBV) Infection, Liver Fibrosis
Non-Invasive Model for Fibrosis Regression in HBV Patients
A total of 1000 chronic hepatitis B (CHB) patients with liver biopsy performed at least 1 year after antiviral therapy are retrospectively enrolled. All the patients received NAs treatment.
- Trial name
- NCT06874127
- Testing
- Nucleos(t)ide Analogs (NA)
- Where
- China
- Volunteers
- 1,100 people
- Sponsor
- Beijing Friendship Hospital